An expert discusses how prurigo nodularis represents one of the most severe itching conditions in dermatology, significantly impacting patients' quality of life and sleep, and explains the importance of breaking the itch-scratch cycle while highlighting recent treatment advances with targeted biologics like dupilumab and nemolizumab.
An expert discusses how to approach a 58-year-old African American woman with severe prurigo nodularis experiencing extreme itch (9/10 rating) and extensive lesions, emphasizing the need for rapid systemic intervention with nemolizumab due to its faster onset of itch relief compared with other biologics.
An expert discusses how to manage a 32-year-old man with both prurigo nodularis and atopic dermatitis who also has asthma, explaining why dupilumab would be the preferred treatment choice over nemolizumab due to safety concerns regarding asthma exacerbation with the latter medication.
An expert discusses how to approach treatment selection in a 68-year-old Latino patient with multiple comorbidities, including chronic kidney disease, emphasizing the importance of considering injection frequency preferences, treatment burden, and the excellent safety profile of targeted biologics in older patients with complex medical histories.
Explore innovative biologic treatments for prurigo nodularis, enhancing patient quality of life and breaking the itch-scratch cycle effectively.
